Display options
Cite
Yildiz A, Aydin B, Gökmen N, et al. Antimanic Treatment With Tamoxifen Affects Brain Chemistry: A Double-Blind, Placebo-Controlled Proton Magnetic Resonance Spectroscopy Study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016;1(2):125-131doi: 10.1016/j.bpsc.2015.12.002.
Yildiz, A., Aydin, B., Gökmen, N., Yurt, A., Cohen, B., Keskinoglu, P., Öngür, D., & Renshaw, P. (2016). Antimanic Treatment With Tamoxifen Affects Brain Chemistry: A Double-Blind, Placebo-Controlled Proton Magnetic Resonance Spectroscopy Study. Biological psychiatry. Cognitive neuroscience and neuroimaging, 1(2), 125-131. https://doi.org/10.1016/j.bpsc.2015.12.002
Yildiz, Ayşegül, et al. "Antimanic Treatment With Tamoxifen Affects Brain Chemistry: A Double-Blind, Placebo-Controlled Proton Magnetic Resonance Spectroscopy Study." Biological psychiatry. Cognitive neuroscience and neuroimaging vol. 1,2 (2016): 125-131. doi: https://doi.org/10.1016/j.bpsc.2015.12.002
Yildiz A, Aydin B, Gökmen N, Yurt A, Cohen B, Keskinoglu P, Öngür D, Renshaw P. Antimanic Treatment With Tamoxifen Affects Brain Chemistry: A Double-Blind, Placebo-Controlled Proton Magnetic Resonance Spectroscopy Study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Mar;1(2):125-131. doi: 10.1016/j.bpsc.2015.12.002. PMID: 27231722; PMCID: PMC4876725.
Copy Download .nbib Format: NLM
Share it on

Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Mar;1(2):125-131. doi: 10.1016/j.bpsc.2015.12.002.

Antimanic Treatment With Tamoxifen Affects Brain Chemistry: A Double-Blind, Placebo-Controlled Proton Magnetic Resonance Spectroscopy Study.

Biological psychiatry. Cognitive neuroscience and neuroimaging

Ayşegül Yildiz, Burç Aydin, Necati Gökmen, Ayşegül Yurt, Bruce Cohen, Pembe Keskinoglu, Dost Öngür, Perry Renshaw

Affiliations

  1. Department of Psychiatry, School of Medicine, Dokuz Eylul University, Izmir, Turkey.
  2. Department of Medical Pharmacology, School of Medicine, Dokuz Eylul University, Izmir, Turkey.
  3. Department of Anesthesiology and Reanimation, School of Medicine, Dokuz Eylul University, Izmir, Turkey.
  4. Department of Medical Physics, Health Sciences Institute, Dokuz Eylul University, ?zmir, Turkey.
  5. Schizophrenia and Bipolar Disorder Program, Mclean Hospital, Belmont, MA, USA.
  6. Department of Biostatistics, School of Medicine, Dokuz Eylul University, Izmir, Turkey.
  7. Brain Institute, University of Utah, Salt Lake City, UT, USA.

PMID: 27231722 PMCID: PMC4876725 DOI: 10.1016/j.bpsc.2015.12.002

Abstract

BACKGROUND: The antimanic efficacy of a protein kinase C (PKC) inhibitor, tamoxifen, has been tested in several clinical trials, all reporting positive results. However, mechanisms underlying the observed clinical effects requires further confirmation through studies of biological markers.

METHODS: We investigated the effect of tamoxifen versus placebo on brain metabolites via a proton (

RESULTS: The YMRS scores decreased from 38.6±4.5 to 20.0±11.1 in the tamoxifen group and increased from 37.0±6.8 to 43.1±7.8 in the placebo group (p<0.001).

CONCLUSIONS: Tamoxifen effectively treated mania while it also increased brain tCr levels, consistent with involvement of both excessive PKC activation and impaired brain energy metabolism in the development of bipolar mania.

CLINICAL TRIAL REGISTRATION: Registry name: ClinicalTrials.gov URL: https://clinicaltrials.gov/ct2/show/NCT00411203?term=NCT00411203&rank=1 Registration number: NCT00411203.

Keywords: MRS; Tamoxifen; bipolar mania; creatine; dorsomedial prefrontal cortex; protein kinase C

References

  1. Arch Gen Psychiatry. 2000 Jan;57(1):95-7 - PubMed
  2. Arch Gen Psychiatry. 2004 May;61(5):450-8 - PubMed
  3. Neuropsychobiology. 2007;55(3-4):123-31 - PubMed
  4. Neuropsychopharmacology. 2001 Apr;24(4):359-69 - PubMed
  5. J ECT. 2010 Jun;26(2):104-10 - PubMed
  6. Psychiatry Clin Neurosci. 2004 Feb;58(1):82-8 - PubMed
  7. Biol Psychiatry. 1993 Apr 1;33(7):520-5 - PubMed
  8. Bipolar Disord. 2007 Sep;9(6):561-70 - PubMed
  9. Psychoneuroendocrinology. 2006 May;31(4):543-7 - PubMed
  10. Curr Neurovasc Res. 2012 Feb;9(1):47-57 - PubMed
  11. J Psychopharmacol. 2012 Dec;26(12):1594-604 - PubMed
  12. J Affect Disord. 2012 Dec 1;141(1):1-10 - PubMed
  13. Biol Psychiatry. 1996 Oct 1;40(7):568-75 - PubMed
  14. Neuropsychopharmacology. 2006 Jun;31(6):1264-73 - PubMed
  15. Int J Neuropsychopharmacol. 2014 Jul;17(7):1039-52 - PubMed
  16. Mol Psychiatry. 2005 Oct;10(10):900-19 - PubMed
  17. Biol Psychiatry. 2006 Jun 15;59(12):1160-71 - PubMed
  18. Bipolar Disord. 2007 Jun;9 Suppl 1:119-27 - PubMed
  19. Int J Neuropsychopharmacol. 2011 Aug;14(7):863-75 - PubMed
  20. Biol Psychiatry. 2002 Feb 1;51(3):195-207 - PubMed
  21. Psychosom Med. 1963 Nov-Dec;25:556-66 - PubMed
  22. J Am Acad Child Adolesc Psychiatry. 2012 Jun;51(6):642-51 - PubMed
  23. Drug Discov Today. 2008 Apr;13(7-8):295-302 - PubMed
  24. Mol Psychiatry. 2015 Sep;20(9):1079-84 - PubMed
  25. Psychiatry Res. 2010 Dec 30;184(3):162-70 - PubMed
  26. Neuropharmacology. 2009 Jan;56(1):47-55 - PubMed
  27. Mol Psychiatry. 1998 Nov;3(6):534-8 - PubMed
  28. Psychiatry Clin Neurosci. 2014 Jul;68(7):551-7 - PubMed
  29. Science. 2004 Oct 29;306(5697):882-4 - PubMed
  30. CNS Drugs. 2009;23(7):569-82 - PubMed
  31. Magn Reson Med. 1993 Dec;30(6):672-9 - PubMed
  32. Am J Pathol. 2010 Aug;177(2):575-85 - PubMed
  33. Arch Gen Psychiatry. 2008 Mar;65(3):255-63 - PubMed
  34. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:40-8 - PubMed
  35. Pharmacol Biochem Behav. 2011 Apr;98(2):304-10 - PubMed
  36. Psychiatry Res. 2012 Aug-Sep;203(2-3):111-25 - PubMed
  37. J Affect Disord. 2011 Mar;129(1-3):327-31 - PubMed
  38. Mol Psychiatry. 2008 Feb;13(2):197-207 - PubMed
  39. Int J Dev Neurosci. 2011 May;29(3):311-24 - PubMed
  40. Neuropsychopharmacology. 2008 Oct;33(11):2551-65 - PubMed

Publication Types

Grant support